Puma Biotechnology (PBYI) Capital Expenditures (2011 - 2025)
Puma Biotechnology's (PBYI) quarterly Capital Expenditures came in at -$36000.0 in Q4 2025, down 200.0% YoY from $36000.0 in Q4 2024, and down 137.11% on a QoQ basis from $97000.0 in Q3 2025.
Powered by 
Analysis
Puma Biotechnology (PBYI) Capital Expenditures (2011 - 2025) Analysis & Trends
Puma Biotechnology (PBYI) has 12 years of Capital Expenditures data on file, last reported at -$36000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 200.0% year-over-year to -$36000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $10000.0 (down 91.45% YoY) and the FY2025 annual result came in at $71000.0, up 26.79% from the prior year.
- Capital Expenditures retreated to -$36000.0 in Q4 2025, from $97000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $97000.0 in Q3 2025 to a low of -$51000.0 in Q2 2025.
- A 3-year average of $15333.3 and a median of $10000.0 in 2024 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 870.0% in 2025, down 610.0% in 2025.
- Tracing PBYI's Capital Expenditures over 3 years: stood at $26000.0 in 2023, then surged by 38.46% to $36000.0 in 2024, then slumped by 200.0% to -$36000.0 in 2025.
- The last three Capital Expenditures figures came in at -$36000.0 (Q4 2025), $97000.0 (Q3 2025), and -$51000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -36,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Jun 30, 2020 | -1,000.00 |
| Mar 31, 2020 | 13,000.00 |
| Dec 31, 2018 | -380,000.00 |
| Sep 30, 2018 | 305,000.00 |
| Jun 30, 2018 | 160,000.00 |
| Mar 31, 2018 | 85,000.00 |
| Dec 31, 2017 | -259,000.00 |